Tuberculosis's Genetic Blueprint Shapes Its Attack on the Body

Why do some tuberculosis (TB) treatments succeed while others fail? A sweeping new study in Georgia suggests the answer lies as much in the bacterium’s genes as in the patient’s health. By analysing the genomes of TB bacteria from over 4,500 patients, researchers have painted a clearer picture of what drives disease outcomes.

Their multivariable modelling confirmed that patient factors matter, but the focus was on the pathogen itself. The investigation revealed that specific bacterial family lines, known as lineages, and mutations conferring resistance to key drugs were linked to unfavourable results and a higher bacterial burden. A genome-wide association study, a method for scanning genomes for links to a trait, found no new mutations directly tied to treatment failure, beyond those already known to cause drug resistance.

However, the study did uncover a surprise: mutations in a bacterial gene called sufD were associated with a less severe infection, including fewer lung cavities. This discovery highlights sufD as a potential therapeutic target and supports the idea of optimising treatment regimens based on the unique genetic signature of the infecting bacteria.